Novel investigations of flavonoids as chemopreventive agents for hepatocellular carcinoma

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Liao, Chen Yi ^a,b   Lee, Ching Chang ^a   Tsai, Chi Chang ^a   Hsueh, Chao Wen ^a   Wang, Chih Chiang ^a   Chen, I Hung ^a   Tsai, Ming Kai ^a   Liu, Mei Yu ^a   Hsieh, An Tie ^a   Su, Kuan Jen ^a   Wu, Hau Ming ^a   Huang, Shih Chung ^a   Wang, Yi Chen ^a   Wang, Chien Yao ^a   Huang, Shu Fang ^a   Yeh, Yen Cheng ^a   Ben, Ren Jy ^a   Chien, Shang Tao ^a   Hsu, Chin Wen ^a   Kuo, Wu Hsien ^a  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BAICALEIN; CHEMOPROPHYLATIC AGENT; EPIGALLOCATECHIN GALLATE; FLAVONOID; GALANGIN; GENISTEIN; OROXYLIN A; QUERCETIN; SILIBININ; UNCLASSIFIED DRUG;

BIOLOGICAL ACTIVITY; CHEMOPROPHYLAXIS; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG RESISTANCE; LIVER NEOPLASMS; METABOLISM; MULTIDRUG RESISTANCE; PATHOLOGY; SIGNAL TRANSDUCTION;

CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HUMANS; LIVER NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84954149608     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/840542     Document Type: Review

References (246)

1. K. W. Burak and M. Sherman, "Hepatocellular carcinoma: consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting, " Canadian Journal of Gastroenterology & Hepatology, vol. 29, no. 4, pp. 178-184, 2015.
2. A. Schlachterman, W. W. Craft Jr., E. Hilgenfeldt, A. Mitra, and R. Cabrera, "Current and future treatments for hepatocellular carcinoma, " World Journal of Gastroenterology, vol. 21, no. 28, pp. 8478-8491, 2015.
3. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, "Global cancer statistics, 2002, " CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74-108, 2005.
4. P. Srivatanakul, H. Sriplung, and S. Deerasamee, "Epidemiology of liver cancer: an overview, " Asian Pacific Journal of Cancer Prevention, vol. 5, no. 2, pp. 118-125, 2004.
5. F. X. Bosch, J. Ribes, M. Diaz, and J. Ribes, "Primary liver cancer: worldwide incidence and trends, " Gastroenterology, vol. 127, no. 5, supplement 1, pp. S5-S16, 2004.
6. M. A. Feitelson, B. Sun, N. L. Satiroglu Tufan, J. Liu, J. Pan, and Z. Lian, "Genetic mechanisms of hepatocarcinogenesis, " Oncogene, vol. 21, no. 16, pp. 2593-2604, 2002.
7. H. O. ElMesallamy, N. S. Metwally, M. S. Soliman, K. A. Ahmed, and M. M. ElMesallamy, "The chemopreventive effectof Ginkgo biloba and Silybummarianum extracts on hepatocarcinogenesis in rats, " Cancer Cell International, vol. 11, no. 1, article 38, 2011.
8. S. Udali, P. Guarini, A. Ruzzenente, et al., "DNA methylation and gene expression profiles show novel regulatory pathways in hepatocellular carcinoma, " Clinical Epigenetics, vol. 7, article 43, 2015.
9. H. V. Tong, C. T. Bock, and T. P. Velavan, "Genetic insights on host and hepatitis B virus in liver diseases, " Mutation Research/Reviews in Mutation Research, vol. 762, pp. 65-75, 2014.
10. M.-A. Buendia and C. Neuveut, "Hepatocellular carcinoma, " Cold SpringHarbor Perspectives inMedicine, vol. 5, no. 2, Article ID a021444, 2015.
11. M. C. Wallace, D. Preen, G. P. Jeffrey, and L. A. Adams, "The evolving epidemiology of hepatocellular carcinoma: a global perspective, " Expert Review of Gastroenterology & Hepatology, vol. 9, no. 6, pp. 765-779, 2015.
12. S. Roayaie, I. N. Blume, S. N. Thung, et al., "A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma, " Gastroenterology, vol. 137, no. 3, pp. 850-855, 2009.
13. Y.-C. Shen, Z.-Z. Lin, C.-H. Hsu, C. Hsu, Y.-Y. Shao, and A.-L. Cheng, "Clinical trials in hepatocellular carcinoma: an update, " Liver Cancer, vol. 2, no. 3-4, pp. 345-364, 2013.
14. J. F. Xia, J. J. Gao, Y. Inagaki, N. Kokudo, M. Nakata, and W. Tang, "Flavonoids as potential anti-hepatocellular carcinoma agents: recent approaches using HepG2 cell line, " Drug Discoveries & Therapeutics, vol. 7, no. 1, pp. 1-8, 2013.
15. R. Kaufmann, P. Henklein, P. Henklein, and U. Settmacher, "Green tea polyphenol epigallocatechin-3-gallate inhibits thrombin-induced hepatocellular carcinoma cell invasion and p42/p44-MAPKinase activation, " Oncology Reports, vol. 21, no. 5, pp. 1261-1267, 2009.
16. X.-L. Chen, Q. Wang, L.-Q. Cao, et al., "Epigallocatechin-3-gallate induces apoptosis in human hepatocellular carcinoma cells, " Zhonghua Yi Xue Za Zhi, vol. 88, no. 36, pp. 2524-2528, 2008.
17. X. Shan, Y. Li, X. Meng, P. Wang, P. Jiang, and Q. Feng, "Curcumin and (-)-epigallocatechin-3-gallate attenuate acrylamide-induced proliferation in HepG2 cells, " Food and Chemical Toxicology, vol. 66, pp. 194-202, 2014.
18. Y. Zhang, L. Owusu, W. Duan, et al., "Anti-metastatic and differential effects on protein expression of epigallocatechin-3-gallate in HCCLM6 hepatocellular carcinoma cells, " International Journal ofMolecularMedicine, vol. 32, no. 4, pp. 959-964, 2013.
19. L. Lu, H.-M. Liu, and W.-X. Tang, "Effect of epigallocatechin-3-gallate on the invasiveness of hepatocarcinoma cells in vitro, " Zhonghua Gan Zang Bing Za Zhi, vol. 15, no. 11, pp. 825-827, 2007.
20. Y.-F. Wang, T. Li, Z.-H. Tang, et al., "Baicalein triggers autophagy and inhibits the protein kinase B/mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells, " Phytotherapy Research, vol. 29, no. 5, pp. 674-679, 2015.
21. Y.-H. Zheng, L.-H. Yin, T. H. M. Grahn, A.-F. Ye, Y.-R. Zhao, and Q.-Y. Zhang, "Anticancer effects of baicalein on hepatocellular carcinoma cells, " Phytotherapy Research, vol. 28, no. 9, pp. 1342-1348, 2014.
22. W. Dai, F. Wang, L. He, et al., "Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelialmesenchymal transition: partial mediation by the transcription factor NFAT1, "Molecular Carcinogenesis, vol. 54, no. 4, pp. 301-311, 2015.
23. M. Xu, N. Lu, Z. Sun, et al., "Activation of the unfolded protein response contributed to the selective cytotoxicity of oroxylin A in human hepatocellular carcinoma HepG2 cells, " Toxicology Letters, vol. 212, no. 2, pp. 113-125, 2012.
24. M. Zou, N. Lu, C. Hu, et al., "Beclin 1-mediated autophagy in hepatocellular carcinoma cells: implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling, " Cellular Signalling, vol. 24, no. 8, pp. 1722-1732, 2012.
25. Y. Wang, J. Wu, B. Lin, et al., "Galangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway, " Toxicology, vol. 326, pp. 9-17, 2014.
26. K. Kiyono, H. I. Suzuki, H. Matsuyama, et al., "Autophagy is activated by TGF-β and potentiates TGF-β-mediated growth inhibition in human hepatocellular carcinoma cells, " Cancer Research, vol. 69, no. 23, pp. 8844-8852, 2009.
27. R. H. Lee, J. H. Cho, Y.-J. Jeon, et al., "Quercetin induces antiproliferative activity against human hepatocellular carcinoma (HepG2) cells by suppressing specificity protein 1 (Sp1), " Drug Development Research, vol. 76, no. 1, pp. 9-16, 2015.
28. Y. Li, S. Duan, H. Jia, C. Bai, L. Zhang, and Z. Wang, "Flavonoids from tartary buckwheat induce G2/M cell cycle arrest and apoptosis in human hepatoma HepG2 cells, " Acta Biochimica et Biophysica Sinica, vol. 46, no. 6, pp. 460-470, 2014.
29. S. Zhang, Y. Yang, Z. Liang, et al., "Silybin-mediated inhibition of notch signaling exerts antitumor activity in human hepatocellular carcinoma cells, " PLoS ONE, vol. 8, no. 12, Article ID e83699, 2013.
30. H. R. Gu, S. C. Park, S. J. Choi, et al., "Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells, " Clinical andMolecularHepatology, vol. 21, no. 1, pp. 49-59, 2015.
31. J. P. Rigalli, N. Ciriaci, A. Arias, et al., "Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity, " PLoS ONE, vol. 10, no. 3, Article ID e0119502, 2015.
32. M. Shimizu, Y. Shirakami, H. Sakai, et al., "EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells, " Cancer letters, vol. 262, no. 1, pp. 10-18, 2008.
33. X. Shen, Y. Zhang, Y. Feng, et al., "Epigallocatechin-3-gallate inhibits cell growth, induces apoptosis and causes S phase arrest in hepatocellular carcinoma by suppressing the AKT pathway, " International Journal of Oncology, vol. 44, no. 3, pp. 791-796, 2014.
34. W. P. Tsang and T. T. Kwok, "Epigallocatechin gallate upregulation of miR-16 and induction of apoptosis in human cancer cells, " The Journal of Nutritional Biochemistry, vol. 21, no. 2, pp. 140-146, 2010.
35. J.-L. Tong, F. Nie, Z.-H. Ran, et al., "Epigallocatechin gallate induces apoptosis in human hepatocellular carcinoma HepG2 cells via TGF/Smad signaling pathway, " Zhonghua Zhong Liu Za Zhi, vol. 31, no. 9, pp. 646-650, 2009.
36. M. M. Darweish, A. Abbas, M. A. Ebrahim, and M. M. H. Al-Gayyar, "Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway, " Journal of Pharmacy and Pharmacology, vol. 66, no. 7, pp. 1032-1045, 2014.
37. K. Chen, S. Zhang, Y. Ji, et al., "Baicalein inhibits the invasion andmetastatic capabilities of hepatocellular carcinoma cells via down-regulation of the ERK pathway, " PLoS ONE, vol. 8, no. 9, Article ID e72927, 2013.
38. W.-H. Chang, C.-H. Chen, R.-J. Gau, et al., "Effect of baicalein on apoptosis of the human Hep G2 cell line was induced by mitochondrial dysfunction, " Planta Medica, vol. 68, no. 4, pp. 302-306, 2002.
39. C.-Y. Jin, C. Park, G.-Y. Kim, S.-J. Lee, W.-J. Kim, and Y. H. Choi, "Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells, " Chemico-Biological Interactions, vol. 180, no. 2, pp. 143-150, 2009.
40. W. Liu, R. Mu, F.-F. Nie, et al., "MACrelated mitochondrial pathway in oroxylin A induces apoptosis in human hepatocellular carcinoma HepG2 cells, " Cancer Letters, vol. 284, no. 2, pp. 198-207, 2009.
41. H.-T. Zhang, J. Wu, M. Wen, L.-J. Su, and H. Luo, "Galangin induces apoptosis in hepatocellular carcinoma cells through the caspase 8/t-Bid mitochondrial pathway, " Journal of Asian Natural Products Research, vol. 14, no. 7, pp. 626-633, 2012.
42. A. B. Granado-Serrano, M. A. Martic, L. Bravo, L. Goya, and S. Ramos, "Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2), " Journal of Nutrition, vol. 136, no. 11, pp. 2715-2721, 2006.
43. M. Momeny, M. R. Khorramizadeh, S. H. Ghaffari, et al., "Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation, " European Journal of Pharmacology, vol. 591, no. 1-3, pp. 13-20, 2008.
44. A. S. Yu and E. B. Keeffe, "Management of hepatocellular carcinoma, " Reviews in Gastroenterological Disorders, vol. 3, no. 1, pp. 8-24, 2003.
45. G. M. Cragg, P. G. Grothaus, and D. J. Newman, "Impact of natural products on developing new anti-cancer agents, " Chemical Reviews, vol. 109, no. 7, pp. 3012-3043, 2009.
46. Y.-L. Cheng, W.-L. Chang, S.-C. Lee, et al., "Acetone extract of Angelica sinensis inhibits proliferation of human cancer cells via inducing cell cycle arrest and apoptosis, " Life Sciences, vol. 75, no. 13, pp. 1579-1594, 2004.
47. J. N. Nwodo, A. Ibezim, C. V. Simoben, and F. Ntie-Kang, "Exploring cancer therapeutics with natural products from African medicinal plants, part II: alkaloids, terpenoids and flavonoids, " Anti-Cancer Agents in Medicinal Chemistry, vol. 16, no. 1, pp. 108-127, 2015.
48. A. Cassidy, G. Rogers, J. J. Peterson, J. T. Dwyer, H. Lin, and P. F. Jacques, "Higher dietary anthocyanin and flavonol intakes are associated with anti-inflammatory effects in a population of US adults, "The American Journal of Clinical Nutrition, vol. 102, no. 1, pp. 172-181, 2015.
49. M. M. de Jeses Romero-Prado, J. A. Curiel-Beltran, M. V. Miramontes-Espino, E. G. Cardona-Munoz, A. Rios-Arellano, and L.-B. Balam-Salazar, "Dietary flavonoids added to pharmacological antihypertensive therapy are effective in improving blood pressure, " Basic and Clinical Pharmacology and Toxicology, vol. 117, no. 1, pp. 57-64, 2015.
50. S. Chirumbolo, "Flavonoids in coronary heart disease, " Thrombosis Research, vol. 135, no. 5, pp. 1040-1041, 2015.
51. Z. Weng, A. B. Patel, S. Panagiotidou, and T. C. Theoharides, "The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells, " Journal of Allergy and Clinical Immunology, vol. 135, no. 4, pp. 1044-1052. e5, 2014.
52. N. F. M. Fozi, M. Mazlan, A. N. Shuid, and I. N. Mohamed, "Milk thistle: a future potential anti-osteoporotic and fracture healing agent, " Current Drug Targets, vol. 14, no. 14, pp. 1659-1666, 2013.
53. W. Dong, X. Wei, F. Zhang, et al., "Adual character of flavonoids in influenza A virus replication and spread through modulating cell-autonomous immunity by MAPK signaling pathways, " Scientific Reports, vol. 4, article 7237, 2014.
54. X.-F. Yang, Y.-L. Wang, and W.-R. Xu, "Reviews on antiviral activity of chemical constituents from plants, " Zhongguo Zhongyao Zazhi, vol. 33, no. 1, pp. 100-104, 2008.
55. X. Song, Y. Chen, Y. Sun, et al., "Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide, " Pharmacological Reports, vol. 64, no. 5, pp. 1189-1199, 2012.
56. Y. C. Jung, M. E. Kim, J. H. Yoon, et al., "Anti-inflammatory effects of galangin on lipopolysaccharide-activated macrophages via ERK and NF-κB pathway regulation, " Immunopharmacology and Immunotoxicology, vol. 36, no. 6, pp. 426-432, 2014.
57. S. Chirumbolo, "Quercetin as a potential anti-allergic drug: which perspectives?" Iranian Journal of Allergy, Asthma and Immunology, vol. 10, no. 2, pp. 139-140, 2011.
58. S.-Y. Lyu, J.-Y. Rhim, and W.-B. Park, "Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type (HSV-2) in vitro, " Archives of Pharmacal Research, vol. 28, no. 11, pp. 1293-1301, 2005.
59. A. E. dos Santos, R. M. Kuster, K. A. Yamamoto, et al., "Quercetin and quercetin 3-O-glycosides from Bauhinia longifolia (Bong.) Steud. show anti-Mayaro virus activity, " Parasites and Vectors, vol. 7, article 130, 2014.
60. N. Horie, N. Hirabayashi, Y. Takahashi, Y. Miyauchi, H. Taguchi, and K. Takeishi, "Synergistic effect of green tea catechins on cell growth and apoptosis induction in gastric carcinoma cells, " Biological and Pharmaceutical Bulletin, vol. 28, no. 4, pp. 574-579, 2005.
61. S. B. Lotito and B. Frei, "Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon?" Free Radical Biology and Medicine, vol. 41, no. 12, pp. 1727-1746, 2006.
62. F.-Y. Tang, N. Nguyen, and M. Meydani, "Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule, " International Journal of Cancer, vol. 106, no. 6, pp. 871-878, 2003.
63. A. Kojima-Yuasa, J. J. Hua, D. O. Kennedy, and I. Matsui-Yuasa, "Green tea extract inhibits angiogenesis of human umbilical vein endothelial cells through reduction of expression of VEGF receptors, " Life Sciences, vol. 73, no. 10, pp. 1299-1313, 2003.
64. N. Khan and H. Mukhtar, "Dietary agents for prevention and treatment of lung cancer, " Cancer Letters, vol. 359, no. 2, pp. 155-164, 2015.
65. A. Srinivasan, C. Thangavel, Y. Liu, et al., "Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer, " Molecular Carcinogenesis, 2015.
66. J. L. Petrick, S. E. Steck, P. T. Bradshaw, et al., "Dietary intake of flavonoids and oesophageal and gastric cancer: incidence and survival in the United States of America (USA), " British Journal of Cancer, vol. 112, no. 7, pp. 1291-1300, 2015.
67. R. Zamora-Ros, V. Fedirko, A. Trichopoulou, et al., "Dietary flavonoid, lignan and antioxidant capacity and risk of hepatocellular carcinoma in the European prospective investigation into cancer and nutrition study, " International Journal of Cancer, vol. 133, no. 10, pp. 2429-2443, 2013.
68. K. Papaj, A. Rusin, W. Szeja, and G. Grynkiewicz, "Absorption and metabolism of biologically active genistein derivatives in colon carcinoma cell line (CACO-2), " Acta Poloniae Pharmaceutica-Drug Research, vol. 71, no. 6, pp. 1037-1044, 2014.
69. Z. Guo, X. Hu, Z. Xing, et al., "Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway, " Molecular and Cellular Biochemistry, vol. 406, no. 1-2, pp. 111-119, 2015.
70. Y. Wang, A. Han, E. Chen, et al., "The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells, " International Journal of Oncology, vol. 46, no. 5, pp. 1924-1934, 2015.
71. R.-H. Chou, S.-C. Hsieh, Y.-L. Yu, M.-H. Huang, Y.-C. Huang, and Y.-H. Hsieh, "Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway, " PLoS ONE, vol. 8, no. 8, Article IDe71983, 2013.
72. K. Sak and H. Everaus, "Chemomodulating effects of flavonoids in human leukemia cells, " Anti-Cancer Agents in Medicinal Chemistry, vol. 15, no. 9, pp. 1112-1126, 2015.
73. J. Schamann, J. Prockl, A. K. Kiemer, A. M. Vollmar, R. Bang, and G. Tiegs, "Silibinin protects mice from T cell-dependent liver injury, " Journal of Hepatology, vol. 39, no. 3, pp. 333-340, 2003.
74. N. Vargas-Mendoza, E. Madrigal-Santilln, A. Morales-Gonzlez, et al., "Hepatoprotective effect of silymarin, " World Journal of Hepatology, vol. 6, no. 3, pp. 144-149, 2014.
75. T. Nishikawa, T. Nakajima, M. Moriguchi, et al., "A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins, " Journal of Hepatology, vol. 44, no. 6, pp. 1074-1082, 2006.
76. R.-R. Liang, S. Zhang, J.-A. N. Qi, et al., "Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling, " International Journal of Oncology, vol. 41, no. 3, pp. 969-978, 2012.
77. T.-C. Yeh, P.-C. Chiang, T.-K. Li, et al., "Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult, " Biochemical Pharmacology, vol. 73, no. 6, pp. 782-792, 2007.
78. Y. Gu, C.-F. Zhu, Y.-L. Dai, Q. Zhong, and B. Sun, "Inhibitory effects of genistein on metastasis of human hepatocellular carcinoma, " World Journal of Gastroenterology, vol. 15, no. 39, pp. 4952-4957, 2009.
79. L. Zhao, Z. Chen, J. Wang, et al., "Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice, " Cancer Chemotherapy and Pharmacology, vol. 65, no. 3, pp. 481-489, 2010.
80. B. Zhu, L. Zhao, L. Zhu, et al., "Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrin1 and its related pathway, " Toxicology and Applied Pharmacology, vol. 259, no. 3, pp. 387-394, 2012.
81. M. Wen, J. Wu, H. Luo, and H. Zhang, "Galangin induces autophagy through upregulation of p53 in HepG2 cells, " Pharmacology, vol. 89, no. 5-6, pp. 247-255, 2012.
82. A. B. Granado-Serrano, M. A. Martic, L. Bravo, L. Goya, and S. Ramos, "Time-course regulation of quercetin on cell survival/proliferation pathways in human hepatoma cells, " Molecular Nutrition and Food Research, vol. 52, no. 4, pp. 457-464, 2008.
83. G. Wang, J. Zhang, L. Liu, S. Sharma, and Q. Dong, "Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl, " PLoSONE, vol. 7, no. 12, Article ID e51764, 2012.
84. D. Moher, D. J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D. F. Stroup, "Improving the quality of reports of meta-analyses of randomised controlled trials: theQUOROMstatement. Quality of Reporting of Meta-analyses, " The Lancet, vol. 354, no. 9193, pp. 1896-1900, 1999.
85. R. N. Abou El Naga, S. S. Azab, E. El-Demerdash, S. Shaarawy, M. El-Merzabani, and E.-S. M. Ammar, "Sensitization of TRAIL-induced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals, " Life Sciences, vol. 92, no. 10, pp. 555-561, 2013.
86. Y. Wang, X. Ren, C. Deng, et al., "Mechanism of the inhibition of the STAT3 signaling pathway by EGCG, " Oncology Reports, vol. 30, no. 6, pp. 2691-2696, 2013.
87. J. Jin, Y. Chang, W. Wei, et al., "Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro, " Acta Pharmacologica Sinica, vol. 33, no. 5, pp. 701-709, 2012.
88. C.-H. Huang, S.-J. Tsai, Y.-J. Wang, M.-H. Pan, J.-Y. Kao, and T.-D. Way, "EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells, " Molecular Nutrition and Food Research, vol. 53, no. 9, pp. 1156-1165, 2009.
89. Y. Shirakami, M. Shimizu, S. Adachi, et al., "(-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis, " Cancer Science, vol. 100, no. 10, pp. 1957-1962, 2009.
90. H.-H. Tang, M. Zhou, and G. Liang, "Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU, " Ai Zheng, vol. 27, no. 10, pp. 1056-1064, 2008.
91. J. L. Sang, W. L. Ki, J. H. Haeng, Y. C. Ji, Y. K. Seo, and J. L. Hyong, "Phenolic phytochemicals derived from red pine (Pinus densiflora) inhibit the invasion and migration of SKHep human hepatocellular carcinoma cells, " Annals of theNew York Academy of Sciences, vol. 1095, pp. 536-544, 2007.
92. Q. Zhang, X. Tang, Q. Lu, Z. Zhang, J. Rao, and A. D. Le, "Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxiaand serum-induced HIF-1 protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells, " Molecular CancerTherapeutics, vol. 5, no. 5, pp. 1227-1238, 2006.
93. Z. Wang, C. Jiang, W. Chen, et al., "Baicalein induces apoptosis and autophagy via endoplasmic reticulum stress in hepatocellular carcinoma cells, " BioMed Research International, vol. 2014, Article ID 732516, 13 pages, 2014.
94. Y.-W. Chiu, T.-H. Lin, W.-S. Huang, et al., "Baicalein inhibits the migration and invasive properties of human hepatoma cells, " Toxicology and Applied Pharmacology, vol. 255, no. 3, pp. 316-326, 2011.
95. H.-M. Kuo, H.-C. Tsai, Y.-L. Lin, et al., "Mitochondrialdependent caspase activation pathway is involved in baicaleininduced apoptosis in human hepatoma J5 cells, " International Journal of Oncology, vol. 35, no. 4, pp. 717-724, 2009.
96. W.-H. Chang, C.-H. Chen, and F.-J. Lu, "Different effects of baicalein, baicalin and wogonin on mitochondrial function, glutathione content and cell cycle progression in human hepatoma cell lines, " PlantaMedica, vol. 68, no. 2, pp. 128-132, 2002.
97. Y. Hu, Y. Yang, Q.-D. You, et al., "Oroxylin A induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity, " Biochemical and Biophysical Research Communications, vol. 351, no. 2, pp. 521-527, 2006.
98. S.-D. Wang, B.-C. Chen, S.-T. Kao, C.-J. Liu, and C.-C. Yeh, "Genistein inhibits tumor invasion by suppressingmultiple signal transduction pathways in human hepatocellular carcinoma cells, " BMC Complementary and Alternative Medicine, vol. 14, article 26, 2014.
99. Y. Ma, J. Wang, L. Liu, et al., "Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-βB, " Cancer Letters, vol. 301, no. 1, pp. 75-84, 2011.
100. S.-C. Fang, C.-L. Hsu, H.-T. Lin, and G.-C. Yen, "Anticancer effects of flavonoid derivatives isolated fromMillettia reticulate benth in sk-hep-1 human hepatocellular carcinoma cells, " Journal of Agricultural and Food Chemistry, vol. 58, no. 2, pp. 814-820, 2010.
101. H. Jiang, Y. Ma, X. Chen, et al., "Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma, " Cancer Science, vol. 101, no. 4, pp. 975-983, 2010.
102. C.-H. Chen, T.-S. Huang, C.-H. Wong, et al., "Synergistic anticancer effect of baicalein and silymarin on human hepatoma HepG2 cells, " Food and Chemical Toxicology, vol. 47, no. 3, pp. 638-644, 2009.
103. L. Su, X. Chen, J. Wu, et al., "Galangin inhibits proliferation of hepatocellular carcinoma cells by inducing endoplasmic reticulum stress, " Food and Chemical Toxicology, vol. 62, pp. 810-816, 2013.
104. H.-T. Zhang, H. Luo, J. Wu, et al., "Galangin induces apoptosis of hepatocellular carcinoma cells via the mitochondrial pathway, " World Journal of Gastroenterology, vol. 16, no. 27, pp. 3377-3384, 2010.
105. J.-L. Zhao, J. Zhao, and H.-J. Jiao, "Synergistic growthsuppressive effects of quercetin and cisplatin on HepG2 human hepatocellular carcinoma cells, " Applied Biochemistry and Biotechnology, vol. 172, no. 2, pp. 784-791, 2014.
106. V. R. Vasquez-Garzan, J. R. MacIas-Parez, M. N. Jimanez-Garcia, V. Villegas, S. Fattel-Fazenta, and S. Villa-Trevino, "The chemopreventive capacity of quercetin to induce programmed cell death in hepatocarcinogenesis, " Toxicologic Pathology, vol. 41, no. 6, pp. 857-865, 2013.
107. J. Zhou, L. Fang, W.-X. Yao, et al., "Effect of quercetin on heat shock protein expression in human hepatocellular carcinoma HepG2 cells determined by SILAC, " Chinese Journal of Oncology, vol. 33, no. 10, pp. 737-741, 2011.
108. A. B. Granado-Serrano, M. A. Martic, L. Bravo, L. Goya, and S. Ramos, "Quercetin modulates NF-kappa B and AP-1/JNK pathways to induce cell death in human hepatoma cells, " Nutrition and Cancer, vol. 62, no. 3, pp. 390-401, 2010.
109. Y.-F. Chang, Y.-C. Hsu, H.-F. Hung, et al., "Quercetin induces oxidative stress and potentiates the apoptotic action of 2-methoxyestradiol in human hepatoma cells, " Nutrition and Cancer, vol. 61, no. 5, pp. 735-745, 2009.
110. J. Y. Kim, E. H. Kim, S. S. Park, J. H. Lim, T. K. Kwon, and K. S. Choi, "Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation, " Journal of Cellular Biochemistry, vol. 105, no. 6, pp. 1386-1398, 2008.
111. W. Cui, F. Gu, and K.-Q. Hu, "Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice, " World Journal of Gastroenterology, vol. 15, no. 16, pp. 1943-1950, 2009.
112. P. Garcia-Maceira and J. Mateo, "Silibinin inhibits hypoxiainducible factor-1 andmTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy, " Oncogene, vol. 28, no. 3, pp. 313-324, 2009.
113. J. J. Lah, W. Cui, and K.-Q. Hu, "Effects and mechanisms of silibinin on human hepatoma cell lines, " World Journal of Gastroenterology, vol. 13, no. 40, pp. 5299-5305, 2007.
114. L. Varghese, C. Agarwal, A. Tyagi, R. P. Singh, and R. Agarwal, "Silibinin efficacy against human hepatocellular carcinoma, " Clinical Cancer Research, vol. 11, no. 23, pp. 8441-8448, 2005.
115. V. Crespy and G. Williamson, "A review of the health effects of green tea catechins in in vivo animal models, " Journal of Nutrition, vol. 134, no. 12, supplement, pp. 3431S-3440S, 2004.
116. G. Z. Yang, Z. J. Wang, F. Bai, et al., "Epigallocatechin-3-gallate protects HUVECs from PM2. 5-induced oxidative stress injury by activating critical antioxidant pathways, " Molecules, vol. 20, no. 4, pp. 6626-6639, 2015.
117. M. Nihal, N. Ahmad, H. Mukhtar, and G. S. Wood, "Antiproliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma, " International Journal of Cancer, vol. 114, no. 4, pp. 513-521, 2005.
118. H. S. Lee, J.-H. Jun, E.-H. Jung, B. A. Koo, and Y. S. Kim, "Epigalloccatechin-3-gallate inhibits ocular neovascularization and vascular permeability in human retinal pigment epithelial and human retinal microvascular endothelial cells via suppression of MMP-9 and VEGF activation, " Molecules, vol. 19, no. 8, pp. 12150-12172, 2014.
119. M. S. Baliga, S. Meleth, and S. K. Katiyar, "Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems, " Clinical Cancer Research, vol. 11, no. 5, pp. 1918-1927, 2005.
120. J.-I. Sonoda, R. Ikeda, Y. Baba, et al., "Green tea catechin, epigallocatechin-3-gallate, attenuates the cell viability of human non-small-cell lung cancer A549 cells via reducing Bcl-xL expression, " Experimental andTherapeutic Medicine, vol. 8, no. 1, pp. 59-63, 2014.
121. D. Zhang, M. Al-Hendy, G. Richard-Davis, V. Montgomery-Rice, V. Rajaratnam, and A. Al-Hendy, "Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells, " Fertility and Sterility, vol. 94, no. 5, pp. 1887-1893, 2010.
122. C. Mayr, A. Wagner, D. Neureiter, et al., "The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells, " BMC Complementary and Alternative Medicine, vol. 15, article 194, 2015.
123. B. N. Singh, S. Shankar, and R. K. Srivastava, "Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications, " Biochemical Pharmacology, vol. 82, no. 12, pp. 1807-1821, 2011.
124. H. Mukhtar and N. Ahmad, "Tea polyphenols: prevention of cancer and optimizing health, "The American Journal of Clinical Nutrition, vol. 71, no. 6, supplement, pp. 1698S-1704S, 2000.
125. M. Shimizu and I. B. Weinstein, "Modulation of signal transduction by tea catechins and related phytochemicals, " Mutation Research: Fundamental andMolecularMechanisms ofMutagenesis, vol. 591, no. 1-2, pp. 147-160, 2005.
126. M. Shimizu, A. Deguchi, J. T. E. Lim, H. Moriwaki, L. Kopelovich, and I. B. Weinstein, "(-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells, " Clinical Cancer Research, vol. 11, no. 7, pp. 2735-2746, 2005.
127. M. Masuda, M. Suzui, J. T. E. Lim, and I. B. Weinstein, "Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells, " Clinical Cancer Research, vol. 9, no. 9, pp. 3486-3491, 2003.
128. V. M. Adhami, I. A. Siddiqui, N. Ahmad, S. Gupta, and H. Mukhtar, "Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer, " Cancer Research, vol. 64, no. 23, pp. 87158722, 2004.
129. Y. D. Jung, M. S. Kim, B. A. Shin, et al., "EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells, " British Journal of Cancer, vol. 84, no. 6, pp. 844-850, 2001.
130. G. Basini, F. Bianco, and F. Grasselli, "EGCG, a major component of green tea, inhibitsVEGF production by swine granulosa cells, " BioFactors, vol. 23, no. 1, pp. 25-33, 2005.
131. S. Shankar, S. Ganapathy, S. R. Hingorani, and R. K. Srivastava, "EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer, " Frontiers in Bioscience, vol. 13, no. 2, pp. 440-452, 2008.
132. T. Sen, S. Moulik, A. Dutta, et al., "Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7, " Life Sciences, vol. 84, no. 7-8, pp. 194-204, 2009.
133. S. K. Denduluri, O. Idowu, Z. Wang, et al., "Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance, " Genes&Diseases, vol. 2, no. 1, pp. 13-25, 2015.
134. B. B. Aggarwal, G. Sethi, S. A. Kwang, et al., "Targeting signaltransducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution, " Annals of the New York Academy of Sciences, vol. 1091, pp. 151-169, 2006.
135. D. G. Hardie, "Molecular pathways: isAMPKa friend or a foe in cancer?" Clinical Cancer Research, vol. 21, no. 17, pp. 3836-3840, 2015.
136. R. Kaufmann, S. Rahn, K. Pollrich, et al., "Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4, " Journal of Cellular Physiology, vol. 211, no. 3, pp. 699-707, 2007.
137. S.-Y. Sun, N. Hail Jr., and R. Lotan, "Apoptosis as a novel target for cancer chemoprevention, " Journal of the National Cancer Institute, vol. 96, no. 9, pp. 662-672, 2004.
138. X.-P. Chen, S.-Q. He, H.-P. Wang, Y.-Z. Zhao, and W.-G. Zhang, "Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosisinducing Ligand in human hepatocellular carcinoma, " World Journal of Gastroenterology, vol. 9, no. 11, pp. 2433-2440, 2003.
139. D. G. Breckenridge, M. Germain, J. P. Mathai, M. Nguyen, and G. C. Shore, "Regulation of apoptosis by endoplasmic reticulum pathways, " Oncogene, vol. 22, no. 53, pp. 8608-8618, 2003.
140. K. Ravasz, A. Tatto, and L. Konta, "Effect of green tea flavanols on the functions of the endoplasmic reticulum, " Orvosi Hetilap, vol. 148, no. 40, pp. 1903-1907, 2007.
141. F. Dituri, A. Mazzocca, J. Fernando, et al., "Differential inhibition of the TGF-β signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF-β receptor type II, " PLoS ONE, vol. 8, no. 6, Article ID e67109, 2013.
142. W. Liu, H. Nakamura, T. Tsujimura, et al., "Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor, " Cancer Science, vol. 97, no. 8, pp. 768-773, 2006.
143. M. A. Kern, A. M. Haugg, A. F. Koch, et al., "Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma, " Cancer Research, vol. 66, no. 14, pp. 7059-7066, 2006.
144. D. G. Menter and R. N. DuBois, "Prostaglandins in cancer cell adhesion, migration, and invasion, " International Journal of Cell Biology, vol. 2012, Article ID 723419, 21 pages, 2012.
145. C. Han, G. K. Michalopoulos, and T. Wu, "Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells, " Journal of Cellular Physiology, vol. 207, no. 1, pp. 261-270, 2006.
146. M. W. Roomi, J. C. Monterrey, T. Kalinovsky, M. Rath, and A. Niedzwiecki, "Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines, " Oncology Reports, vol. 24, no. 3, pp. 747-757, 2010.
147. K. H. Kim, Y. D. Park, H. Park, et al., "Synthesis and biological evaluation of a novel baicalein glycoside as an antiinflammatory agent, " European Journal of Pharmacology, vol. 744, pp. 147-156, 2014.
148. J. Y. Wu, K. T. Chung, Y. W. Liu, F. J. Lu, R. S. Tsai, and C. H. Chen, "Synthesis and biological evaluation of novel C(6) modified baicalein derivatives as antioxidative agents, " Journal of Agricultural and Food Chemistry, vol. 56, no. 8, pp. 2838-2845, 2008.
149. L. Gao, C. Li, R.-Y. Yang, et al., "Ameliorative effects of baicalein in MPTP-induced mouse model of Parkinsons disease: a microarray study, " Pharmacology Biochemistry and Behavior, vol. 133, pp. 155-163, 2015.
150. Y. Huang, S.-Y. Tsang, X. Yao, and Z.-Y. Chen, "Biological properties of baicalein in cardiovascular system, " Current Drug Target-Cardiovascular&Hematological Disorders, vol. 5, no. 2, pp. 177-184, 2005.
151. A. Ahad, M. Mujeeb, H. Ahsan, and W. A. Siddiqui, "Prophylactic effect of baicalein against renal dysfunction in type 2 diabetic rats, " Biochimie, vol. 106, pp. 101-110, 2014.
152. Y. Zhang, L. Shan, Y. Hua, et al., "Baicalein selectively induces apoptosis in activated lymphocytes and ameliorates concanavalin a-induced hepatitis in mice, " PLoS ONE, vol. 8, no. 7, Article ID e69592, 2013.
153. H.-J. Chen, T.-M. Liang, I.-J. Lee, Y.-T. Huang, and Y.-L. Lin, "Scutellariae radix suppresses LPS-induced liver endothelial cell activation and inhibits hepatic stellate cell migration, " Journal of Ethnopharmacology, vol. 150, no. 3, pp. 835-842, 2013.
154. H.-B. Zhang, P. Lu, Q.-Y. Guo, Z.-H. Zhang, and X.-Y. Meng, "Baicalein induces apoptosis in esophageal squamous cell carcinoma cells through modulation of the PI3K/Akt pathway, " Oncology Letters, vol. 5, no. 2, pp. 722-728, 2013.
155. J. Y. Wu, K. W. Tsai, Y. Z. Li, et al., "Anti-bladder-tumor effect of Baicalein from Scutellaria baicalensis Georgi and its application in vivo, " Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 579751, 12 pages, 2013.
156. D. H. Kim, M. A. Hossain, Y. J. Kang, et al., "Baicalein, an active component of Scutellaria baicalensis Georgi, induces apoptosis in human colon cancer cells and prevents AOM/DSS-induced colon cancer in mice, " International Journal of Oncology, vol. 43, no. 5, pp. 1652-1658, 2013.
157. G. Donald, K. Hertzer, and G. Eibl, "Baicalein-an intriguing therapeutic phytochemical in pancreatic cancer, " Current Drug Targets, vol. 13, no. 14, pp. 1772-1776, 2012.
158. P. Puri and A. Chandra, "Autophagy modulation as a potential therapeutic target for liver diseases, " Journal of Clinical and Experimental Hepatology, vol. 4, no. 1, pp. 51-59, 2014.
159. Y. Y. Zhou, Y. Li, W. Q. Jiang, and L. F. Zhou, "MAPK/JNK signalling: a potential autophagy regulation pathway, " Bioscience Reports, vol. 35, no. 3, Article IDe00199, 2015.
160. F. Wang, J. L. Yang, K. K. Yu, et al., "Activation of the NF-κB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma, " Molecular Cancer, vol. 14, article 10, 2015.
161. T. Luedde and R. F. Schwabe, "NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma, " Nature Reviews Gastroenterology & Hepatology, vol. 8, no. 2, pp. 108-118, 2011.
162. D.-P. Ou, Y.-M. Tao, F.-Q. Tang, and L.-Y. Yang, "Thehepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases, " International Journal of Cancer, vol. 120, no. 6, pp. 1208-1214, 2007.
163. T. Itoh, Y. Hayashi, T. Kanamaru, et al., "Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma, " Journal of Gastroenterology and Hepatology, vol. 15, no. 4, pp. 422-430, 2000.
164. J. Cheng, J. Qi, X.-T. Li, et al., "ATRA and genistein synergistically inhibit the metastatic potential of human lung adenocarcinoma cells, " International Journal of Clinical and Experimental Medicine, vol. 8, no. 3, pp. 47220-4227, 2015.
165. DG. Pons, M. Nadal-Serrano, M. Torrens-Mas, J. Oliver, and P. Roca, "The phytoestrogen genistein affects breast cancer cells treatment depending on the ER/ER ratio, " Journal of Cellular Biochemistry, 2015.
166. W. Huang, C. Wan, Q. Luo, Z. Huang, and Q. Luo, "Genisteininhibited cancer stemcell-like properties and reduced chemoresistance of gastric cancer, " International Journal of Molecular Sciences, vol. 15, no. 3, pp. 3432-3443, 2014.
167. Y. Luo, S. X. Wang, Z. Q. Zhou, et al., "Apoptotic effect of genistein on human colon cancer cells via inhibiting the nuclear factor-kappa B (NF-κB) pathway, " Tumor Biology, vol. 35, no. 11, pp. 11483-11488, 2014.
168. M. N. Dastjerdi, F. Kavoosi, A. Valiani, et al., "Inhibitory effect of genistein on PLC/PRF5 hepatocellular carcinoma cell line, " International Journal of Preventive Medicine, vol. 6, article 54, 2015.
169. Y. Wu, L. Zhang, R. Na, et al., "Plasma genistein and risk of prostate cancer in Chinese population, " International Urology and Nephrology, vol. 47, no. 6, pp. 965-970, 2015.
170. Y.-S. Li, L.-P. Wu, K.-H. Li, et al., "Involvement of nuclear factor βB (NF-κB) in the downregulation of cyclo-oxygenase-2 (COX-2) by genistein in gastric cancer cells, " Journal of International Medical Research, vol. 39, no. 6, pp. 2141-2150, 2011.
171. M. S. Tsuboy, J. C. Marcarini, A. O. de Souza, et al., "Genistein at maximal physiologic serum levels induces G0/G1 arrest in MCF-7 and HB4a cells, but not apoptosis, " Journal of Medicinal Food, vol. 17, no. 2, pp. 218-225, 2014.
172. S. H. Kim, C. W. Kim, S. Y. Jeon, R. E. Go, K. A. Hwang, and K. C. Choi, "Chemopreventive and chemotherapeutic effects of genistein, a soy isoflavone, upon cancer development and progression in preclinical animal models, " Laboratory Animal Research, vol. 30, no. 4, pp. 143-150, 2014.
173. Y. Sun, W. Z. Liu, T. Liu, X. Feng, N. Yang, and H. F. Zhou, "Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis, " Journal of Receptors and Signal Transduction, 2015.
174. F. van Zijl, G. Zulehner, M. Petz, et al., "Epithelial-mesenchymal transition in hepatocellular carcinoma, " Future Oncology, vol. 5, no. 8, pp. 1169-1179, 2009.
175. M. Ye, Q. Wang, W. Zhang, Z. Li, Y. Wang, and R. Hu, "Oroxylin A exerts anti-inflammatory activity on lipopolysaccharideinduced mouse macrophage via Nrf2/ARE activation, " Biochemistry and Cell Biology, vol. 92, no. 5, pp. 337-348, 2014.
176. S.-C. Ma, J. Du, P. P.-H. But, et al., "Antiviral Chinese medicinal herbs against respiratory syncytial virus, " Journal of Ethnopharmacology, vol. 79, no. 2, pp. 205-211, 2002.
177. H.-T. Trinh, E.-H. Joh, H.-Y. Kwak, N.-I. Baek, and D.-H. Kim, "Anti-pruritic effect of baicalin and its metabolites, baicalein and oroxylin A, in mice, " Acta Pharmacologica Sinica, vol. 31, no. 6, pp. 718-724, 2010.
178. D. H. Kim, S. J. Jeon, K. H. Son, et al., "Effect of the flavonoid, oroxylin A, on transient cerebral hypoperfusion-induced memory impairment in mice, " Pharmacology Biochemistry and Behavior, vol. 85, no. 3, pp. 658-668, 2006.
179. R. Zhu, G. Zeng, Y. Chen, et al., "Oroxylin A accelerates liver regeneration in CCI4-induced acute liver injury mice, " PLoS ONE, vol. 8, no. 8, Article ID e71612, 2013.
180. L. Wei, Q. Dai, Y. Zhou, et al., "Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II, " Biochimica et Biophysica Acta: General Subjects, vol. 1830, no. 6, pp. 3835-3845, 2013.
181. L. Wei, Y. Zhou, C. Qiao, et al., "Oroxylin A inhibits glycolysisdependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1 destabilization, " Cell Death and Disease, vol. 6, no. 4, Article IDe1714, 2015.
182. Y. Yang, Y. Hu, H.-Y. Gu, et al., "Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells, " Journal of Pharmacy and Pharmacology, vol. 60, no. 11, pp. 1459-1463, 2008.
183. C. Qiao, L. Wei, Q. Dai, et al., "UCP2-related mitochondrial pathway participates in oroxylinA-induced apoptosis in human colon cancer cells, " Journal of Cellular Physiology, vol. 230, no. 5, pp. 1054-1063, 2015.
184. H.-N. Li, F.-F. Nie, W. Liu, et al., "Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo, " Toxicology, vol. 257, no. 1-2, pp. 80-85, 2009.
185. H. Hui, Y. Chen, H. Yang, et al., "Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPAR and RXR, " International Journal of Cancer, vol. 134, no. 5, pp. 1195-1206, 2014.
186. X. Meng, D. A. Franklin, J. Dong, and Y. Zhang, "MDM2-p53 pathway in hepatocellular carcinoma, " Cancer Research, vol. 74, no. 24, pp. 7161-7167, 2014.
187. R. Mu, Q. Qi, H. Gu, et al., "Involvement of p53 in oroxylin A-induced apoptosis in cancer cells, " Molecular Carcinogenesis, vol. 48, no. 12, pp. 1159-1169, 2009.
188. T. P. T. Cushnie and A. J. Lamb, "Assessment of the antibacterial activity of galangin against 4-quinolone resistant strains of Staphylococcus aureus, " Phytomedicine, vol. 13, no. 3, pp. 187-191, 2006.
189. G. Duthie and P. Morrice, "Antioxidant capacity of flavonoids in hepatic microsomes is not reflected by antioxidant effects in vivo, " Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 165127, 6 pages, 2012.
190. H. H. Kim, Y. Bae, and S. H. Kim, "Galangin attenuates mast cell-mediated allergic inflammation, " Food and Chemical Toxicology, vol. 57, pp. 209-216, 2013.
191. S. Kumar and K. R. Alagawadi, "Anti-obesity effects of galangin, a pancreatic lipase inhibitor in cafeteria diet fed female rats, " Pharmaceutical Biology, vol. 51, no. 5, pp. 607-613, 2013.
192. S. Li, C. Wu, L. Zhu, et al., "By improving regional cortical blood flow, attenuating mitochondrial dysfunction and sequential apoptosis galangin acts as a potential neuroprotective agent after acute ischemic stroke, "Molecules, vol. 17, no. 11, pp. 13403-13423, 2012.
193. S. Kapoor, "Galangin and its emerging anti-neoplastic effects, " Cytotechnology, vol. 65, no. 4, pp. 467-468, 2013.
194. X. Zhao and J. Zhang, "Inhibitory effect of galangin on DNA topoisomerases in lung cancer cells, " Zhong Nan Da Xue Xue Bao Yi Xue Ban, vol. 40, no. 5, pp. 479-485, 2015.
195. L. Zhu, Q. Luo, J. Bi, J. Ding, S. Ge, and F. Chen, "Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo, " Chemico-Biological Interactions, vol. 224, pp. 149-156, 2014.
196. T. J. Murray, X. Yang, and D. H. Sherr, "Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by downregulation of cyclins D3, E, and A, " Breast Cancer Research, vol. 8, no. 2, article R17, 2006.
197. T. K. Ha, M. E. Kim, J. H. Yoon, S. J. Bae, J. Yeom, and J. S. Lee, "Galangin induces human colon cancer cell death via the mitochondrial dysfunction and caspase-dependent pathway, " Experimental Biology and Medicine, vol. 238, no. 9, pp. 1047-1054, 2013.
198. H. Huang, A. Y. Chen, Y. Rojanasakul, X. Ye, G. O. Rankin, and Y. C. Chen, "Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis, " Journal of Functional Foods, vol. 15, pp. 464-475, 2015.
199. A. Monasterio, M. C. Urdaci, I. V. Pinchuk, N. Lopez-Moratalla, and J. J. Marticez-Irujo, "Flavonoids induce apoptosis in human leukemia U937 cells through caspase-and caspase-calpaindependent pathways, " Nutrition and Cancer, vol. 50, no. 1, pp. 90-100, 2004.
200. W. Zhang, Y. Lan, Q. Huang, and Z. Hua, "Galangin induces B16F10 melanoma cell apoptosis viamitochondrial pathway and sustained activation of p38 MAPK, " Cytotechnology, vol. 65, no. 3, pp. 447-455, 2013.
201. C. C. Pan, S. Kumar, N. Shah, et al., "Endoglin regulation of Smad2 function mediates beclin1 expression and endothelial autophagy, "The Journal of Biological Chemistry, vol. 290, no. 24, pp. 14884-14892, 2015.
202. S. T. Chien, M. D. Shi, Y. C. Lee, C. C. Te, and Y. W. Shih, "Galangin, a novel dietary flavonoid, attenuates metastatic feature via PKC/ERK signaling pathway in TPA-treated liver cancer HepG2 cells, " Cancer Cell International, vol. 15, article 15, 2015.
203. V. S. Rogovskii, N. L. Shimanovskii, and A. I. Matiushin, "Antihypertensive and neuroprotective activity of quercetin and its derivatives, " Eksp Klin Farmakol, vol. 75, no. 9, pp. 37-41, 2012.
204. R. Huang, T. Zhong, and H. Wu, "Quercetin protects against lipopolysaccharide-induced acute lung injury in rats through suppression of inflammation and oxidative stress, " Archives of Medical Science, vol. 11, no. 2, pp. 427-432, 2015.
205. M. Belviranli and N. Okudan, "Well-known antioxidants and newcomers in sport nutrition: coenzyme Q10, quercetin, resveratrol, pterostilbene, pycnogenol and astaxanthin, " in Antioxidants in Sport Nutrition, M. Lamprecht, Ed., chapter 5, CRC Press, Boca Raton, Fla, USA, 2015.
206. A. M. L. Hossion and K. Sasaki, "Novel quercetin glycosides as potent anti-MRSA and anti-VRE agents, " Recent Patents on Anti-Infective Drug Discovery, vol. 8, no. 3, pp. 198-205, 2013.
207. H. M. Eid, A. Nachar, F. Thong, G. Sweeney, and P. S. Haddad, "The molecular basis of the antidiabetic action of quercetin in cultured skeletal muscle cells and hepatocytes, " Pharmacognosy Magazine, vol. 11, no. 41, pp. 74-81, 2015.
208. M. Waseem and S. Parvez, "Neuroprotective activities of curcumin and quercetin with potential relevance to mitochondrial dysfunction induced by oxaliplatin, " Protoplasma, 2015.
209. E. Rajesh, L. S. Sankari, L. Malathi, and J. R. Krupaa, "Naturally occurring products in cancer therapy, " Journal of Pharmacy And Bioallied Sciences, vol. 7, supplement 1, pp. S181-S183, 2015.
210. X. Zhao and J. Zhang, "Mechanisms for quercetin in prevention of lung cancer cell growth and metastasis, " Zhong Nan Da Xue Xue Bao Yi Xue Ban, vol. 40, no. 6, pp. 592-597, 2015.
211. J.-Y. Zhang, M.-T. Lin, M.-J. Zhou, et al., "Combinational treatment of curcumin and quercetin against gastric cancer MGC-803 cells in vitro, " Molecules, vol. 20, no. 6, pp. 11524-11534, 2015.
212. M. G. Refolo, R. D'Alessandro, N. Malerba, et al., "Anti proliferative and pro apoptotic effects of flavonoid quercetin are mediated by CB1 receptor in human colon cancer cell lines, " Journal of Cellular Physiology, vol. 230, no. 12, pp. 2973-2980, 2015.
213. F. Yang, L. Song, H. Wang, J. Wang, Z. Xu, and N. Xing, "Combination of quercetin and 2-methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells Xenograft tumor growth, " PLoS ONE, vol. 10, no. 5, Article ID e0128277, 2015.
214. J. Zhou, J. Gong, C. Ding, and G. Chen, "Quercetin induces the apoptosis of human ovarian carcinoma cells by upregulating the expression of microRNA-145, " Molecular Medicine Reports, vol. 12, no. 2, pp. 3127-3131, 2015.
215. Y. Hu, S. Wang, X. Wu, et al., "Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma, " Journal of Ethnopharmacology, vol. 149, no. 3, pp. 601-612, 2013.
216. V. Vasquez-Garzan, J. Arellanes-Robledo, R. Garcia-Roman, D. Aparicio-Rautista, and S. Villa-Trevino, "Inhibition of reactive oxygen species and pre-neoplastic lesions by quercetin through an antioxidant defense mechanism, " Free Radical Research, vol. 43, no. 2, pp. 128-137, 2009.
217. Y.-F. Chang, N.-W. Chi, and J.-J. Wang, "Reactive oxygen species production is involved in quercetin-induced apoptosis in human hepatoma cells, " Nutrition and Cancer, vol. 55, no. 2, pp. 201-209, 2006.
218. S. Oztark, K. Schleich, and I. N. Lavrik, "Cellular FLICElike inhibitory proteins (c-FLIPs): fine-tuners of life and death decisions, " Experimental Cell Research, vol. 318, no. 11, pp. 1324-1331, 2012.
219. W. J. Lu, N. P. Lee, S. Fatima, and J. M. Luk, "Heat shockproteins in cancer: signaling pathways, tumor markers and molecular targets in liver malignancy, " Protein and Peptide Letters, vol. 16, no. 5, pp. 508-516, 2009.
220. A. Sharma, A. K. Upadhyay, and M. K. Bhat, "Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells, " Cancer Biology and Therapy, vol. 8, no. 22, pp. 2106-2113, 2009.
221. K. Wellington and B. Jarvis, "Silymarin: a review of its clinical properties in the management of hepatic disorders, " BioDrugs, vol. 15, no. 7, pp. 465-489, 2001.
222. R. K. Dhiman and Y. K. Chawla, "Herbal medicines for liver diseases, " Digestive Diseases and Sciences, vol. 50, no. 10, pp. 1807-1812, 2005.
223. G. Mallikarjuna, S. Dhanalakshmi, R. P. Singh, C. Agarwal, and R. Agarwal, "Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling, " Cancer Research, vol. 64, no. 17, pp. 6349-6356, 2004.
224. X. Wang, E. Gocek, V. Novik, J. S. Harrison, M. Danilenko, and G. P. Studzinski, "Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and upregulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1, 25-dihydroxyvitamin D3, " Cell Cycle, vol. 9, no. 22, pp. 4542-4551, 2010.
225. D. K. Nambiar, P. Rajamani, and R. P. Singh, "Silibinin attenuates ionizing radiation-induced pro-angiogenic response and EMT in prostate cancer cells, " Biochemical and Biophysical Research Communications, vol. 456, no. 1, pp. 262-268, 2015.
226. R. Kumar, G. Deep, and R. Agarwal, "An overview of ultraviolet B radiation-induced skin cancer chemoprevention by silibinin, " Current Pharmacology Reports, vol. 1, no. 3, pp. 206-215, 2015.
227. Z. Liang, Y. Yang, H. Wang, et al., "Inhibition of SIRT1 signaling sensitizes the antitumor activity of silybin against human lung adenocarcinoma cells in vitro and in vivo, " Molecular Cancer Therapeutics, vol. 13, no. 7, pp. 1860-1872, 2014.
228. M. B. Pirouzpanah, M. Sabzichi, S. Pirouzpanah, H. Chavoshi, and N. Samadi, "Silibilin-induces apoptosis in breast cancer cells by modulating p53, p21, Bak and Bcl-XL pathways, " Asian Pacific Journal of Cancer Prevention, vol. 16, no. 5, pp. 2087-2092, 2015.
229. S. Kumar, K. Raina, C. Agarwal, and R. Agarwal, "Silibinin strongly inhibits the growth kinetics of colon cancer stem cellenriched spheroids by modulating interleukin 4/6-mediated survival signals, " Oncotarget, vol. 5, no. 13, pp. 4972-4989, 2014.
230. K. Wu, Z. Ning, J. Zeng, et al., "Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dualblocking epithelial-mesenchymal transition and stemness, " Cellular Signalling, vol. 25, no. 12, pp. 2625-2633, 2013.
231. M. Osaki, M. Oshimura, and H. Ito, "PI3K-Akt pathway: its functions and alterations in human cancer, " Apoptosis, vol. 9, no. 6, pp. 667-676, 2004.
232. Z. X. Qiu, S. Zhao, L. Li, and W. M. Li, "Loss of expression of PTEN is associated with worse prognosis in patients with cancer, " Asian Pacific Journal of Cancer Prevention, vol. 16, no. 11, pp. 4691-4698, 2015.
233. X.-L. Chen, J.-P. Fu, J. Shi, P. Wan, H. Cao, and Z.-M. Tang, "CXC195 induces apoptosis and endoplastic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway, " Molecular Medicine Reports, vol. 12, no. 6, pp. 8229-8236, 2015.
234. A. Villanueva, C. Alsinet, K. Yanger, et al., "Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice, " Gastroenterology, vol. 143, no. 6, pp. 1660.e7-1669.e7, 2012.
235. R. Ghasemi, S. H. Ghaffari, M. Momeny, et al., "Multitargeting and antimetastatic potentials of silibinin in humanHepG-2 and PLC/PRF/5 hepatoma cells, " Nutrition and Cancer, vol. 65, no. 4, pp. 590-599, 2013.
236. O. Kucera, V. Mezera, A. Moravcova, et al., "In vitro toxicity of epigallocatechin gallate in rat liver mitochondria and hepatocytes, " Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 476180, 10 pages, 2015.
237. D. Wang, Y. Wang, X. Wan, C. S. Yang, and J. Zhang, "Green tea polyphenol (-)-epigallocatechin-3-gallate triggered hepatotoxicity in mice: responses of major antioxidant enzymes and theNrf2 rescue pathway, " Toxicology andApplied Pharmacology, vol. 283, no. 1, pp. 65-74, 2015.
238. M. Li, A. Shi, H. Pang, et al., "Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects, " Journal of Ethnopharmacology, vol. 156, pp. 210-215, 2014.
239. A. B. Siegel, R. Narayan, R. Rodriguez, et al., "A phase I dosefinding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma, " Integrative CancerTherapies, vol. 13, no. 1, pp. 46-53, 2014.
240. X. Yanyu, S. Yunmei, C. Zhipeng, and P. Qineng, "The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats, " International Journal of Pharmaceutics, vol. 307, no. 1, pp. 77-82, 2006.
241. Y. Yun, Y. W. Cho, and K. Park, "Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery, " Advanced Drug Delivery Reviews, vol. 65, no. 6, pp. 822-832, 2013.
242. R.-L. Duan, X. Sun, J. Liu, T. Gong, and Z.-R. Zhang, "Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility, " Acta Pharmacologica Sinica, vol. 32, no. 1, pp. 108-115, 2011.
243. K. A. Khaled, Y. M. El-Sayed, and B. M. Al-Hadiya, "Disposition of the flavonoid quercetin in rats after single intravenous and oral doses, " Drug Development and Industrial Pharmacy, vol. 29, no. 4, pp. 397-403, 2003.
244. A. K. Mandal, D. Ghosh, S. Sarkar, A. Ghosh, S. Swarnakar, and N. Das, "Nanocapsulated quercetin downregulates rat hepatic MMP-13 and controls diethylnitrosamine-induced carcinoma, " Nanomedicine, vol. 9, no. 15, pp. 2323-2337, 2014.
245. F. Dajas, "Life or death: neuroprotective and anticancer effects of quercetin, " Journal of Ethnopharmacology, vol. 143, no. 2, pp. 383-396, 2012.
246. P. Chen, M.-D. Hu, X.-F. Deng, and B. Li, "Genistein reinforces the inhibitory effect of cisplatin on liver cancer recurrence and metastasis after curative hepatectomy, " Asian Pacific Journal of Cancer Prevention, vol. 14, no. 2, pp. 759-764, 2013.